// App-Quantinova.ai

4019 : Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib Experience At a Single Institution

Researchers

Presenter

  • Preetesh Jain

Principal Investigators

  • Hagop M. Kantarjian

  • Carlos Guillermo Romo

  • Farhad Ravandi

  • Susan -Brien

  • Jorge Cortes

  • Alfonso Quintas-Cardama

  • Elias Jabbour

  • Marylou Cardenas-Turanzas

  • Sherry Pierce

  • Mary Joy Liboon

  • Evguenia Gachimova

  • Tapan M. Kadia

  • Gautam Borthakur

Medical Centers

  • Department of Radiology, MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Urology

Disease

  • Myocardial infarction

  • Transient Ischemic Attack

  • Transient ischemic attack

  • Chronic Myelogenous Leukemia

  • Hypercholesterolemia, Familial, 1

  • Dyslipidemia

  • Male Sexual Dysfunction

  • Arrhythmia

  • Venous thrombosis

  • Thrombocytopenia

  • Hypertension

  • Pancreatitis

  • Pericarditis

  • Neutropenia

  • Angina

  • Depression

  • Xerostomia

  • Melanoma

  • Epilepsy

Biomarkers

  • Ret Proto-Oncogene

  • Fibroblast growth factor receptor

  • Fms related tyrosine kinase 3

  • Body mass index

Drug/Treatment

  • Ponatinib

  • L-Tyrosine

  • lipase

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved